PhD Scientific Days 2025

Poster Session II. - O: Health Sciences

Risk Factors for the Progression of Acute Pancreatitis to Recurrent and Chronic Forms: A Systematic Review and Meta-Analysis

Name of the presenter

Gagyi Endre-Botond

Institute/workplace of the presenter

Center for Translational Medicine, Semmelweis University

Authors

Dr. Endre Botond Gagyi¹

1: Center for Translational Medicine, Semmelweis University

Text of the abstract

Background: The transition of acute pancreatitis (AP) into recurrent (RAP) and chronic pancreatitis (CP) presents significant clinical challenges. Identifying risk factors for this progression is essential for improving prevention and management strategies.
Methods: We conducted a systematic review and meta-analysis following a registered protocol on PROSPERO (CRD42022368931). A comprehensive literature search was performed in Medline, Embase, and Cochrane databases up to October 19, 2024, to identify studies examining risk factors associated with the evolution of AP into RAP or CP. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model. Heterogeneity was assessed using the I² statistic, and the risk of bias was evaluated using the Quality in Prognostic Studies (QUIPS) tool.
Results: A total of 128 studies were included. Several factors were identified as significant contributors to the recurrence of AP, including male gender (OR: 1.49, 95% CI: 1.31-1.62, I²=25%), smoking (OR: 1.47, 95% CI: 1.22-1.71, I²=57%), alcoholic etiology (OR: 1.78, 95% CI: 1.45-2.14, I²=78%), hypertriglyceridemia (OR: 2.48, 95% CI: 2.16-2.83, I²=9%), diabetes mellitus (OR: 1.51, 95% CI: 1.21-1.75, I²=0%), and pseudocysts (OR: 2.23, 95% CI: 1.61-3.12, I²=0%). Additionally, risk factors for the progression from RAP to CP were identified. The overall risk of bias was moderate in most included studies.
Conclusion: The findings highlight several modifiable risk factors associated with the progression of pancreatitis. Addressing these factors may play a crucial role in preventing disease advancement and improving patient outcomes.
Funding was provided by the the EKÖP-2024-197 New National Excellence Program of the Ministry For Culture And Innovation from the source of the national research, development and innovation fund.